A UF team found that two popular glucose-lowering medications may have neuroprotective effects against Alzheimer’s disease and related dementias. They studied Medicare claims data of older adults with Type 2 diabetes and found a statistically significant association between reduced risk of Alzheimer’s and the use of GLP-1RAs and SGLT2is compared with other glucose-lowering medications.
“There is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer’s disease prevention in the future. As use of these drugs continues to expand, it becomes increasingly important to understand their real-world benefits and risks across populations,” says Serena Jingchuan Guo. Next steps include evaluating the effects of the drugs in broader populations.
View Related Expert Profiles: Go to Source
